MEK (Mitogen-activated protein kinase kinase, MAPKK) is a kinase enzyme which phosphorylates mitogen-activated protein kinase (MAPK). The activators of p38 (MKK3 and MKK6), JNK (MKK4 and MKK7), and ERK (MEK1 and MEK2) define independent MAP kinase signal transduction pathways. The acronym MEK derives from Mitogen/Extracellular signal-regulated Kinase. MEK is a member of the MAPK signaling cascade that is activated in melanoma. When MEK is inhibited, cell proliferation is blocked and apoptosis (controlled cell death) is induced.
**MEK Inhibitors & Modulators**

**AS703026**  
(Pimasertib; MSC1936369B; AS-703026; AS 703026)  
Cat. No.: HY-12042

**Bioactivity:** AS703026(Pimasertib) is a highly selective, potent, ATP non-competitive allosteric inhibitor of MEK1/2 with IC50 of 5 nM-2 μM in MM cell lines.

**Purity:** 99.95%  
**Clinical Data:** Phase 2  
**Size:** 10 mM x 1 mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg

**AZD8330**  
(ARRY-424704; ARRY-704; AZD-8330; ARRY424704; ARRY704; AZD8330)  
Cat. No.: HY-12058

**Bioactivity:** AZD8330(ARRY-424704; ARRY-704) is a novel, selective, non-ATP competitive MEK 1/2 inhibitor with IC50 of 7 nM

**Purity:** 98%  
**Clinical Data:** Phase 1  
**Size:** 10 mM x 1 mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg

**BI-847325**  
(BI847325; BI 847325)  
Cat. No.: HY-18955

**Bioactivity:** BI-847325 is an ATP competitive dual inhibitor of MEK1 and aurora kinases (AK) with IC50 values of 4 and 15 nM for human MEK2 and AK-C, respectively.

**Purity:** > 98%  
**Clinical Data:** Phase 2  
**Size:** 10 mM x 1 mL in DMSO, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

**BIX02188**  
(BIX 02188; BIX-02188)  
Cat. No.: HY-12056

**Bioactivity:** BIX02188 is a selective inhibitor of MEK5 with IC50 of 49 nM

**Purity:** 99.65%  
**Clinical Data:**  
**Size:** 10 mM x 1 mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg

**CI-1040**  
(CI1040; CI 1040; PD184352; PD-184352; PD 184352)  
Cat. No.: HY-50295

**Bioactivity:** CI-1040 (PD 184352) is an ATP non-competitive MEK1/2 inhibitor with IC50 of 17 nM, 100-fold more selective for MEK1/2 than MEK5

**Purity:** > 98.0%  
**Clinical Data:** Phase 3  
**Size:** 10 mM x 1 mL in DMSO, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg, 200 mg

**Cobimetinib (GDC-0973; XL-518; GDC 0973; XL 518)**  
Cat. No.: HY-13064

**Bioactivity:** Cobimetinib is a novel selective MEK inhibitor, and the IC50 value against MEK1 is 4.2 nM.

**Purity:** 99.59%  
**Clinical Data:** Phase 1, Phase 3  
**Size:** 10 mM x 1 mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg

**Cobimetinib (R-enantiomer) (GDC-0973 R-enantiomer; XL-518 R-enantiomer)**  
Cat. No.: HY-13079

**Bioactivity:** Cobimetinib (R-enantiomer) (GDC-0973, XL518) is the R-enantiomer of Cobimetinib, which is a potent, highly selective inhibitor of mitogen-activated protein kinase kinase(MEK1/2).

**Purity:** > 98%  
**Clinical Data:** Phase 1, Phase 3  
**Size:** 10 mM x 1 mL in DMSO, 5 mg

**Cobimetinib (racemate) (GDC-0973 racemate; XL-518; GDC 0973; XL 518)**  
Cat. No.: HY-13078

**Bioactivity:** Cobimetinib(GDC-0973; XL518) is a potent, highly selective inhibitor of MEK1/2.

**Purity:** 99.9%  
**Clinical Data:** Phase 1, Phase 3  
**Size:** 10 mM x 1 mL in DMSO, 5 mg, 10 mg, 50 mg

**GDC-0623**  
(GDC0623; GDC 0623)  
Cat. No.: HY-15610

**Bioactivity:** GDC-0623 is a potent, ATP-uncompetitive inhibitor of MEK1 (K_i=0.13 nM, +ATP), and displays 6-fold weaker potency against HCT116 (KRAS (G13D), EC50=42 nM) versus A375 (BRAF^V600E, EC50=7 nM).

**Purity:** > 95.0%  
**Clinical Data:** Phase 2  
**Size:** 10 mM x 1 mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg

**Bioactivity:** GDC-0623 is a potent, ATP-uncompetitive inhibitor of MEK1 (K_i=0.13 nM, +ATP), and displays 6-fold weaker potency against HCT116 (KRAS (G13D), EC50=42 nM) versus A375 (BRAF^V600E, EC50=7 nM).

**Purity:** > 95.0%  
**Clinical Data:** Phase 2  
**Size:** 10 mM x 1 mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg

Tel: 609-228-6898  Fax: 609-228-5909  Email: sales@medchemexpress.com
<table>
<thead>
<tr>
<th><strong>Bioactivity</strong>: Honokiol (NSC-293100), a hydroxylated biphenyl compound isolated from the Chinese herb Magnolia officinalis, has been reported to have anticancer activities in a variety of cancer cell lines</th>
<th><strong>Bioactivity</strong>: Isorhamnetin is an O-methylated flavonol, a flavonoid aglucon.</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Purity</strong>: 99.71%</td>
<td><strong>Purity</strong>: 98%</td>
</tr>
<tr>
<td><strong>Clinical Data</strong>:</td>
<td><strong>Clinical Data</strong>:</td>
</tr>
<tr>
<td>Size: 10mM x 1mL in DMSO, 50 mg, 100 mg, 200 mg</td>
<td>Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg, 50 mg</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Bioactivity</strong>: MEK inhibitor (1H-Indole-6-carboxamide, 3-[[3-[(dimethylamino)methyl]phenyl]amino]phenylmethylene)-2,3-dihydro-N-m...</th>
<th><strong>Bioactivity</strong>: MEK162 is a potent and selective mitogen-activated protein kinase (MEK) inhibitor with IC$_{50}$ of 12 nM.</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Purity</strong>: &gt; 98%</td>
<td><strong>Purity</strong>: 98.61%</td>
</tr>
<tr>
<td><strong>Clinical Data</strong>:</td>
<td><strong>Clinical Data</strong>:</td>
</tr>
<tr>
<td>Size: 10mM x 1mL in DMSO, 5 mg, 10 mg</td>
<td>Size: 10mM x 1mL in DMSO, 10 mg, 50 mg, 100 mg, 200 mg</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Bioactivity</strong>: OTS964 is a potent TOPK inhibitor with an IC50 value of 28 nM.</th>
<th><strong>Bioactivity</strong>: PD0325901 is a selective and non ATP-competitive MEK inhibitor with IC$_{50}$ of 0.33 nM, roughly 500-fold more potent than CI-1040 on phosphorylation of ERK1 and ERK2.</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Purity</strong>: 98.62%</td>
<td><strong>Purity</strong>: 99.95%</td>
</tr>
<tr>
<td><strong>Clinical Data</strong>:</td>
<td><strong>Clinical Data</strong>:</td>
</tr>
<tr>
<td>Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg</td>
<td>Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Bioactivity</strong>: PD318088 is a non-ATP competitive allosteric MEK1/2 inhibitor, binds simultaneously with ATP in a region of the MEK1 active site that is adjacent to the ATP-binding site.</th>
<th><strong>Bioactivity</strong>: PD98059 is an MEK inhibitor with IC$<em>{50}$ of 5 μM, also suppresses TCDD binding to the aryl hydrocarbon receptor (AHR) with IC$</em>{50}$ of 4 μM.</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Purity</strong>: 99.35%</td>
<td><strong>Purity</strong>: 99.45%</td>
</tr>
<tr>
<td><strong>Clinical Data</strong>:</td>
<td><strong>Clinical Data</strong>:</td>
</tr>
<tr>
<td>Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg</td>
<td>Size: 10mM x 1mL in DMSO, 10 mg, 50 mg, 100 mg</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Bioactivity</strong>: Refametinib (BAY 869766; BAY 86-97661; RDEA-119; RDEA119) is an orally bioavailable selective MEK inhibitor with potential antineoplastic activity (IC50=19 nM MEK1, IC50=47 nM MEK2).</th>
<th><strong>Bioactivity</strong>: Refametinib R enantiomer (BAY 869766 R enantiomer; RDEA119 R enantiomer; BAY ...) is the only cyclopropane-1-sulfonamide derivative, and exhibits a highly selective allosteric inhibition of MEK 1/2.</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Purity</strong>: 99.82%</td>
<td><strong>Purity</strong>: &gt; 98%</td>
</tr>
<tr>
<td><strong>Clinical Data</strong>:</td>
<td><strong>Clinical Data</strong>:</td>
</tr>
<tr>
<td>Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg</td>
<td>Size: 1 mg</td>
</tr>
</tbody>
</table>

---
**Ro 5126766**  
(Ro5126766; Ro 5126766; CH-5126766; CH5126766; CH 5126766)  
Cat. No.: HY-18652

**Bioactivity:**  
Ro 5126766 (CH5126766) is a potent and selective dual RAF/MEK inhibitor. For SK-MEL-28, SK-MEL-2, MIAPaCa-2, and SW480 cell lines, the IC50 is determined by WST-8 assay is 65, 28, 40, and 46 nM, respectively.

**Purity:**  >98.0%

**Clinical Data:**  
Phase 1

**Size:**  
10mM x 1mL in DMSO, 5mg, 10mg, 50mg, 100mg

---

**RO4987655**  
(RO-4987655; RO 4987655; CH-4987655; CH4987655; CH 4987655)  
Cat. No.: HY-14719

**Bioactivity:**  
RO4987655(CH-4987655) is an orally active small molecule, targeting mitogen-activated protein kinase kinase 1 (MAP2K1/MEK1 IC50=5.2 nM), with potential antineoplastic activity.

**Purity:**  98.22%

**Clinical Data:**  
Phase 1

**Size:**  
10mM x 1mL in DMSO, 5mg, 10mg, 50mg

---

**Selumetinib**  
(AZD6244; Array142886; ARRY-142886, AZD-6244)  
Cat. No.: HY-50706

**Bioactivity:**  
Selumetinib is a highly potent MEK inhibitor, with an IC50 value of 14 nM against MEK1.

**Purity:**  99.46%

**Clinical Data:**  
Phase 2, Phase 3

**Size:**  
10mM x 1mL in DMSO, 50mg, 100mg, 200mg, 500mg, 1g

---

**TAK-733**  
(TAK733; TAK 733)  
Cat. No.: HY-13449

**Bioactivity:**  
TAK-733 is a potent and selective MEK allosteric site inhibitor for MEK1 with IC50 of 3.2 nM, inactive to Abl1, AKT3, c-RAF, CamK1, CDK2, c-Met, etc.

**Purity:**  98.74%

**Clinical Data:**  
Phase 1

**Size:**  
10mM x 1mL in DMSO, 5mg, 10mg, 50mg

---

**SL327**  
(SL 327; SL-327)  
Cat. No.: HY-15437

**Bioactivity:**  
SL-327 is a cell-permeable vinylogous cyanamide that acts as a selective inhibitor of MEK-1 and MEK-2 (IC50 = 0.18 and 0.22 μM respectively).

**Purity:**  >98%

**Clinical Data:**  
Phase 2, Phase 3

**Size:**  
10mM x 1mL in DMSO, 5mg, 10mg, 50mg

---

**Trametinib (DMSO solvate)**  
(GSK-1120212 DMSO solvate; Trametinib; JTP-74057; GSK1120212; GSK 1120212; JTP-74057; JTP74057)  
Cat. No.: HY-10999

**Bioactivity:**  
Trametinib (DMSO solvate) is a potent MEK1/2 inhibitor that specifically inhibits MEK1/2, with an IC50 value of about 2 nM.

**Purity:**  99.05%

**Clinical Data:**  
Phase 2, Phase 3

**Size:**  
10mM x 1mL in DMSO, 10mg, 50mg, 100mg

---

**Trametinib**  
(GSK-1120212; JTP 74057; GSK1120212; GSK 1120212; JTP-74057; JTP74057)  
Cat. No.: HY-10999

**Bioactivity:**  
Trametinib is a potent MEK1/2 inhibitor that specifically inhibits MEK1/2, with an IC50 value of about 2 nM.

**Purity:**  99.05%

**Clinical Data:**  
Phase 2, Phase 3

**Size:**  
10mM x 1mL in DMSO, 10mg, 50mg, 100mg

---

**U0126**  
(UO126–EtOH; U 0126; U-0126)  
Cat. No.: HY-12031

**Bioactivity:**  
U0126 is a non-ATP competitive MEK inhibitor, with IC50 of 70 nM and 60 nM for MEK1 and MEK2, respectively.

**Purity:**  98.03%

**Clinical Data:**  
Phase 1

**Size:**  
10mM x 1mL in DMSO, 10mg, 50mg, 100mg, 200mg, 500mg